Barclays raised the firm’s price target on Eli Lilly to $420 from $400 and keeps an Overweight rating on the shares post the Q1 results. Mounjaro commercial acceleration continues and the SURMOUNT-2 hurdle has been cleared, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LLY:
- Eli Lilly price target raised to $430 from $421 at Truist
- Eli Lilly price target raised to $485 from $432 at Cantor Fitzgerald
- Eli Lilly price target raised to $420 from $400 at Credit Suisse
- Eli Lilly price target raised to $430 from $400 at JPMorgan
- Eli Lilly price target raised to $447 from $438 at UBS
